Joanne E Tomassini

US Patent:

20040110717, Jun 10, 2004

Filed:

Jan 16, 2004

Appl. No.:

10/250873

Inventors:

Steven Carroll - Yardley PA, US
Robert LaFemina - Schwenksville PA, US
Dawn Hall - Spring City PA, US
Amy Himmelberger - Lansdale PA, US
Lawrence Kuo - Gwynedd Valley PA, US
David Olsen - Lansdale PA, US
Carrie Rutkowski - Lansdale PA, US
Joanne Tomassini - Lower Gwynedd PA, US
Malcolm MacCoss - Freehold NJ, US
Haoyun An - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Neelima Bhat - Carlsbad CA, US
Phillip Cook - Fallbrook CA, US
Anne Eldrup - Encinitas CA, US
Thazha Prakash - Carlsbad CA, US
Marija Prhavc - Carlsbad CA, US
Charles Guinosso - Chestnut Ridge NY, US

International Classification:

A61K031/7076
A61K031/7072
A61K031/519
A61K031/513
A61K031/498
A61K031/4433

US Classification:

514/045000, 514/050000, 514/249000, 514/262100, 514/269000, 514/340000

Abstract:

The present invention provides nucleoside derivatives which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside derivatives alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside derivatives of the present invention.

US Patent:

46147934, Sep 30, 1986

Filed:

Mar 2, 1984

Appl. No.:

6/585942

Inventors:

Joseph V. Hughes - Harleysville PA
Edward M. Scolnick - Wynnewood PA
Joanne E. Tomassini - Harleysville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07K 1504

US Classification:

530350

Abstract:

A surface structural protein of Hepatitis A Virus (HAV) has been isolated and characterized from virus grown in tissue culture. This 33,000 dalton viral protein (VP-1) reacts with immune HAV sera and monoclonal antibodies that neutralize HAV infectivity. The VP-1 is usable for the preparation of a polypeptide subunit vaccine for HAV. Hybridoma cells were made which produced monoclonal antibodies to HAV or VP-1. These monoclonal antibodies were found to neutralize the infectivity of HAV and to compete with polyclonal antibody derived from human HAV immune sera. The monoclonal antibodies are useful for the neutralization of infectious HAV, the detection of antibodies to neutralizing sites on HAV, and the diagnoses of HAV disease in humans and other susceptible hosts.

US Patent:

54751098, Dec 12, 1995

Filed:

Oct 17, 1994

Appl. No.:

8/324190

Inventors:

Harold G. Selnick - Ambler PA
Gerald S. Ponticello - Lansdale PA
John J. Baldwin - Gwynedd Valley PA
Joanne E. Tomassini - Lansdale PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D21132
C07D40106

US Classification:

546225

Abstract:

Dioxobutanoic acids substituted with piperidine or similar N-substituted saturated cycloalkyls are found to inhibit the cap-dependent endonuclease of influenza virus. These compounds are useful in the prevention or treatment of infection by influenza virus and the treatment of influenza, either as compound, pharmaceutically acceptable salts,. pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating influenza and methods of preventing or treating infection by influenza virus are also described.

US Patent:

56188307, Apr 8, 1997

Filed:

Sep 29, 1995

Appl. No.:

8/536294

Inventors:

Harold G. Selnick - Ambler PA
John J. Baldwin - Gwynedd Valley PA
Gerald S. Ponticello - Lansdale PA
Joanne E. Tomassini - Lansdale PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3144
A61K 31445

US Classification:

514358

Abstract:

Dioxobutanoic acids substituted with piperidine or similar N-substituted saturated cycloalkyls are found to inhibit the cap-dependent endonuclease of influenza virus. These compounds are useful in the prevention or treatment of infection by influenza virus and the treatment of influenza, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating influenza and methods of preventing or treating infection by influenza virus are also described.